Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy.
Yoshihiro KitaharaYusuke InoueHideki YasuiMasato KarayamaYuzo SuzukiHironao HozumiKazuki FuruhashiNoriyuki EnomotoTomoyuki FujisawaKazuhito FunaiTetsuya HondaKiyoshi MisawaHideaki MiyakeHiroya TakeuchiNaoki InuiTakafumi SudaPublished in: Respiratory research (2024)
Patients with lung cancer were at high risk of developing DIILD in subsequent regimens after ICI treatment. Whether NSCLC patients are predisposed to additional risk of docetaxel-induced ILD by prior ICIs warrants further study.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- end stage renal disease
- high glucose
- diabetic rats
- ejection fraction
- small cell lung cancer
- chronic kidney disease
- newly diagnosed
- stem cells
- squamous cell carcinoma
- peritoneal dialysis
- papillary thyroid
- oxidative stress
- advanced non small cell lung cancer
- mesenchymal stem cells
- bone marrow
- lymph node metastasis
- endothelial cells
- combination therapy
- stress induced
- childhood cancer
- clinical evaluation